Neuromodulation for Chronic Pelvic Pain: A Single-Institution Experience With a Collaborative Team.


Journal

Neurosurgery
ISSN: 1524-4040
Titre abrégé: Neurosurgery
Pays: United States
ID NLM: 7802914

Informations de publication

Date de publication:
15 03 2021
Historique:
received: 10 04 2020
accepted: 10 10 2020
pubmed: 30 12 2020
medline: 12 5 2021
entrez: 29 12 2020
Statut: ppublish

Résumé

Secondary to the complex care, involved specialty providers, and various etiologies, chronic pelvic pain patients do not receive holistic care. To compare our general and neuromodulation cohorts based on referrals, diagnosis, and therapy and describe our neuromodulation patients. A multidisciplinary team was established at our center. The intake coordinator assessed demographics and facilitated care of enrolled patients. Outcomes were compared using minimal clinical important difference of current Numerical Rating Scale (NRS) between patients with neuropathic pain who received neuromodulation and those who did not. The neuromodulation cohort completed outcome metrics at baseline and recent follow-up, including NRS score (best, worst, and current), Oswestry Disability Index (ODI), Beck Depression Inventory, and Pain Catastrophizing Scale. Over 7 yr, 233 patients were referred to our consortium and 153 were enrolled. A total of 55 patients had neuropathic pain and 44 of those were managed medically. Eleven underwent neuromodulation. A total of 45.5% patients of the neuromodulation cohort were classified as responders by minimal clinically important difference compared to 26.6% responders in the control cohort at most recent follow-up (median 25 and 33 mo, respectively). Outcome measures revealed improvement in NRS at worst (P = .007) and best (P = .025), ODI (P = .014), and Pain Catastrophizing Scale Rumination (P = .043). Eleven percent of patients were offered neuromodulation. There were more responders in the neuromodulation cohort than the conservatively managed neuropathic pain cohort. Neuromodulation patients showed significant improvement at 29 mo in NRS best and worst pain, disability, and rumination. We share our algorithm for patient management.

Sections du résumé

BACKGROUND
Secondary to the complex care, involved specialty providers, and various etiologies, chronic pelvic pain patients do not receive holistic care.
OBJECTIVE
To compare our general and neuromodulation cohorts based on referrals, diagnosis, and therapy and describe our neuromodulation patients.
METHODS
A multidisciplinary team was established at our center. The intake coordinator assessed demographics and facilitated care of enrolled patients. Outcomes were compared using minimal clinical important difference of current Numerical Rating Scale (NRS) between patients with neuropathic pain who received neuromodulation and those who did not. The neuromodulation cohort completed outcome metrics at baseline and recent follow-up, including NRS score (best, worst, and current), Oswestry Disability Index (ODI), Beck Depression Inventory, and Pain Catastrophizing Scale.
RESULTS
Over 7 yr, 233 patients were referred to our consortium and 153 were enrolled. A total of 55 patients had neuropathic pain and 44 of those were managed medically. Eleven underwent neuromodulation. A total of 45.5% patients of the neuromodulation cohort were classified as responders by minimal clinically important difference compared to 26.6% responders in the control cohort at most recent follow-up (median 25 and 33 mo, respectively). Outcome measures revealed improvement in NRS at worst (P = .007) and best (P = .025), ODI (P = .014), and Pain Catastrophizing Scale Rumination (P = .043).
CONCLUSION
Eleven percent of patients were offered neuromodulation. There were more responders in the neuromodulation cohort than the conservatively managed neuropathic pain cohort. Neuromodulation patients showed significant improvement at 29 mo in NRS best and worst pain, disability, and rumination. We share our algorithm for patient management.

Identifiants

pubmed: 33372201
pii: 6054605
doi: 10.1093/neuros/nyaa537
pmc: PMC7956019
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

819-827

Informations de copyright

© Congress of Neurological Surgeons 2020.

Références

Ann R Coll Surg Engl. 2008 Sep;90(6):497-9
pubmed: 18598595
Pain Pract. 2015 Apr;15(4):293-9
pubmed: 24690212
Eur J Pain. 2015 Oct;19(9):1342-9
pubmed: 25766681
J Minim Invasive Gynecol. 2013 Nov-Dec;20(6):811-8
pubmed: 23981982
Drug Alcohol Depend. 2017 Apr 01;173 Suppl 1:S11-S21
pubmed: 28363315
Pain Med. 2018 Oct 1;19(10):2009-2015
pubmed: 29522121
Spine (Phila Pa 1976). 2000 Nov 15;25(22):2940-52; discussion 2952
pubmed: 11074683
Pain. 1992 May;49(2):221-230
pubmed: 1535122
Neurosurgery. 2017 Dec 1;81(6):1011-1015
pubmed: 28973581
J Pain Symptom Manage. 2002 Oct;24(4):379-87
pubmed: 12505206
Baillieres Best Pract Res Clin Obstet Gynaecol. 2000 Jun;14(3):525-39
pubmed: 10962640
Arch Rheumatol. 2015 Oct 23;31(1):102-103
pubmed: 29900974
Brain Sci. 2018 Sep 29;8(10):
pubmed: 30274287
Neuromodulation. 2018 Apr;21(3):234-246
pubmed: 29377442
Health Psychol. 2001 Mar;20(2):112-9
pubmed: 11315728
J Urol. 2001 Nov;166(5):1742-5
pubmed: 11586214
Br J Neurosurg. 2016 Dec;30(6):685-686
pubmed: 27425005
Pain Pract. 2018 Jul;18(6):805-809
pubmed: 29106051
Ther Adv Urol. 2019 Jun 26;11:1756287219857271
pubmed: 31263510
Am J Obstet Gynecol. 2005 May;192(5):1663-8
pubmed: 15902174
Gastroenterology. 2005 Jun;128(7):1953-64
pubmed: 15940629
Pain Physician. 2009 May-Jun;12(3):633-8
pubmed: 19461829
Int Neurourol J. 2017 Dec;21(4):243-246
pubmed: 29298475
J Pain Res. 2018 Oct 16;11:2367-2374
pubmed: 30410389

Auteurs

Cheyanne Bridger (C)

Department of Neurosurgery, Albany Medical College, Albany, New York.
Department of Neuroscience and Experimental Therapeutics, Albany Medical College, Albany, New York.

Tarun Prabhala (T)

Department of Neuroscience and Experimental Therapeutics, Albany Medical College, Albany, New York.

Rachael Dawson (R)

Department of Neuroscience and Experimental Therapeutics, Albany Medical College, Albany, New York.

Olga Khazen (O)

Department of Neuroscience and Experimental Therapeutics, Albany Medical College, Albany, New York.

Jacquelyn MacDonell (J)

Department of Neuroscience and Experimental Therapeutics, Albany Medical College, Albany, New York.

Marisa DiMarzio (M)

Department of Neuroscience and Experimental Therapeutics, Albany Medical College, Albany, New York.

Michael D Staudt (MD)

Department of Neurosurgery, Albany Medical College, Albany, New York.

Elise J B De (EJB)

Department of Urology, Massachusetts General Hospital, Boston, Massachusetts.

Charles Argoff (C)

Department of Neurology, Albany Medical College, Albany, New York.

Julie G Pilitsis (JG)

Department of Neurosurgery, Albany Medical College, Albany, New York.
Department of Neuroscience and Experimental Therapeutics, Albany Medical College, Albany, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH